Vertex Pharmaceuticals Incorporated (VRTX) PE Ratio: 25.92
Is Vertex Pharmaceuticals Incorporated’s P/E ratio high or low?
Vertex Pharmaceuticals Incorporated's P/E ratio of 25.92 is in line with its 5-year average of 27.23, around the middle of its 5-year range (17.86–34.14).
The P/E ratio for Vertex Pharmaceuticals Incorporated (VRTX) is 25.92 as of Wednesday, June 10, 2026. It is below its 12-month average by 12.26% (29.54).
PE Ratio (25.92) = Close Price ($436.96) / Diluted TTM EPS ($16.86)
VRTX PE Ratio Chart
VRTX Average PE Ratio Chart
VRTX Current vs Average PE Ratio Chart
VRTX PE Ratio Metrics
PE RATIO
25.92
PE RATIO AVG TTM
29.54
PE RATIO AVG 3Y
29.28
PE RATIO AVG 5Y
27.23
PE RATIO AVG 10Y
54.82
PE RATIO AVG 15Y
101.70
PE RATIO AVG 20Y
101.70
CURRENT VS TTM AVG
-12.26%
CURRENT VS 3Y AVG
-11.47%
CURRENT VS 5Y AVG
-4.80%
CURRENT VS 10Y AVG
-52.72%
CURRENT VS 15Y AVG
-74.51%
CURRENT VS 20Y AVG
-74.51%
VRTX Competitors' PE Ratio
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) | — | 25.92 | 29.54 | 29.28 | 27.23 |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 15.70 | 17.63 | 16.34 | 19.37 |
| Medtronic plc (MDT) | $103.04B | 21.52 | 25.27 | 27.00 | 28.75 |
| CVS Health Corporation (CVS) | $125.16B | 43.22 | 81.81 | 37.72 | 30.77 |
| Danaher Corporation (DHR) | $130.25B | 35.67 | 41.62 | 38.62 | 34.94 |
| Elevance Health Inc. (ELV) | $87.43B | 17.13 | 13.84 | 16.38 | 17.76 |
| Cigna Corporation (CI) | $78.25B | 12.54 | 13.87 | 19.16 | 16.74 |
| Pfizer Inc. (PFE) | $146.36B | 19.58 | 16.36 | 22.40 | 18.18 |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 50.15 | 65.94 | 75.04 | 71.85 |
| Gilead Sciences, Inc. (GILD) | $151.21B | 16.58 | 21.34 | 157.50 | 110.62 |
P/E vs. its own history
At 25.9, P/E is cheaper than usual — richer than 30% of its 14-year range.
14-year low
17.9
median
29.1
14-year high
3208.0
P/E Comparison
Trailing P/E
25.9
Forward P/E
20.2
Forward P/E Calculation
View All Analyst EstimatesForward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$436.96
Forward EPS (Est.)
$21.62
Forward P/E
20.21
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
Vertex Pharmaceuticals Incorporated PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Vertex Pharmaceuticals Incorporated PE Ratio FAQ
- What is the P/E ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The P/E ratio for VRTX stock is 25.92.
- Is Vertex Pharmaceuticals Incorporated's P/E ratio high or low?
- Vertex Pharmaceuticals Incorporated's P/E ratio of 25.92 is in line with its 5-year average of 27.23, around the middle of its 5-year range (17.86–34.14).
- What is the TTM average P/E ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The TTM average P/E ratio for VRTX stock is 29.54.
- What is the 3Y average P/E ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 3Y average P/E ratio for VRTX stock is 29.28.
- What is the 5Y average P/E ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 5Y average P/E ratio for VRTX stock is 27.23.
- What is the 10Y average P/E ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 10Y average P/E ratio for VRTX stock is 54.82.
- What is the 15Y average P/E ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 15Y average P/E ratio for VRTX stock is 101.70.
- What is the 20Y average P/E ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 20Y average P/E ratio for VRTX stock is 101.70.
Vertex Pharmaceuticals Incorporated PE Ratio History
| DATE | PE RATIO |
|---|---|
| 2026-06-10 | 25.92 |
| 2026-06-09 | 26.44 |
| 2026-06-08 | 26.27 |
| 2026-06-05 | 26.50 |
| 2026-06-04 | 26.20 |
| 2026-06-03 | 25.41 |
| 2026-06-02 | 25.21 |
| 2026-06-01 | 26.00 |
| 2026-05-29 | 26.54 |
| 2026-05-28 | 26.57 |
| 2026-05-27 | 25.93 |
| 2026-05-26 | 25.86 |
| 2026-05-22 | 25.77 |
| 2026-05-21 | 25.71 |
| 2026-05-20 | 25.53 |
| 2026-05-19 | 25.76 |
| 2026-05-18 | 25.89 |
| 2026-05-15 | 25.92 |
| 2026-05-14 | 26.71 |
| 2026-05-13 | 26.87 |
| 2026-05-12 | 26.59 |
| 2026-05-11 | 25.81 |
| 2026-05-08 | 25.49 |
| 2026-05-07 | 25.21 |
| 2026-05-06 | 25.36 |
| 2026-05-05 | 25.17 |
| 2026-05-04 | 28.04 |
| 2026-05-01 | 27.65 |
| 2026-04-30 | 27.88 |
| 2026-04-29 | 27.61 |
| 2026-04-28 | 28.06 |
| 2026-04-27 | 27.79 |
| 2026-04-24 | 28.07 |
| 2026-04-23 | 28.38 |
| 2026-04-22 | 28.55 |
| 2026-04-21 | 28.48 |
| 2026-04-20 | 28.65 |
| 2026-04-17 | 28.78 |
| 2026-04-16 | 28.42 |
| 2026-04-15 | 28.81 |
| 2026-04-14 | 28.98 |
| 2026-04-13 | 28.71 |
| 2026-04-10 | 28.46 |
| 2026-04-09 | 29.14 |
| 2026-04-08 | 28.96 |
| 2026-04-07 | 28.17 |
| 2026-04-06 | 28.33 |
| 2026-04-02 | 28.62 |
| 2026-04-01 | 29.18 |
| 2026-03-31 | 29.13 |
| 2026-03-30 | 28.91 |
| 2026-03-27 | 28.25 |
| 2026-03-26 | 29.60 |
| 2026-03-25 | 29.68 |
| 2026-03-24 | 29.26 |
| 2026-03-23 | 29.44 |
| 2026-03-20 | 29.62 |
| 2026-03-19 | 29.88 |
| 2026-03-18 | 29.46 |
| 2026-03-17 | 30.17 |
| 2026-03-16 | 30.40 |
| 2026-03-13 | 30.62 |
| 2026-03-12 | 31.19 |
| 2026-03-11 | 32.12 |
| 2026-03-10 | 32.56 |
| 2026-03-09 | 30.06 |
| 2026-03-06 | 29.79 |
| 2026-03-05 | 30.06 |
| 2026-03-04 | 31.17 |
| 2026-03-03 | 30.94 |
| 2026-03-02 | 31.70 |
| 2026-02-27 | 32.41 |
| 2026-02-26 | 31.32 |
| 2026-02-25 | 31.51 |
| 2026-02-24 | 31.80 |
| 2026-02-23 | 31.38 |
| 2026-02-20 | 31.11 |
| 2026-02-19 | 30.61 |
| 2026-02-18 | 30.68 |
| 2026-02-17 | 31.14 |
| 2026-02-13 | 32.06 |
| 2026-02-12 | 32.79 |
| 2026-02-11 | 32.53 |
| 2026-02-10 | 32.69 |
| 2026-02-09 | 33.21 |
| 2026-02-06 | 33.70 |
| 2026-02-05 | 32.36 |
| 2026-02-04 | 33.18 |
| 2026-02-03 | 32.84 |
| 2026-02-02 | 33.29 |
| 2026-01-30 | 33.14 |
| 2026-01-29 | 33.55 |
| 2026-01-28 | 33.70 |
| 2026-01-27 | 33.44 |
| 2026-01-26 | 33.63 |
| 2026-01-23 | 33.03 |
| 2026-01-22 | 32.96 |
| 2026-01-21 | 32.52 |
| 2026-01-20 | 31.18 |
| 2026-01-16 | 31.13 |
| 2026-01-15 | 30.95 |
| 2026-01-14 | 31.70 |
| 2026-01-13 | 32.06 |
| 2026-01-12 | 32.48 |
| 2026-01-09 | 32.71 |
| 2026-01-08 | 33.12 |
| 2026-01-07 | 34.14 |
| 2026-01-06 | 33.03 |
| 2026-01-05 | 31.65 |
| 2026-01-02 | 31.89 |
| 2025-12-31 | 31.97 |
| 2025-12-30 | 32.00 |
| 2025-12-29 | 32.42 |
| 2025-12-26 | 32.64 |
| 2025-12-24 | 32.65 |
| 2025-12-23 | 32.38 |
| 2025-12-22 | 32.46 |
| 2025-12-19 | 32.17 |
| 2025-12-18 | 31.55 |
| 2025-12-17 | 31.70 |
| 2025-12-16 | 32.08 |
| 2025-12-15 | 32.14 |
| 2025-12-12 | 31.88 |
| 2025-12-11 | 31.45 |
| 2025-12-10 | 31.36 |
| 2025-12-09 | 30.82 |
| 2025-12-08 | 31.17 |
| 2025-12-05 | 32.12 |
| 2025-12-04 | 32.25 |
| 2025-12-03 | 32.66 |
| 2025-12-02 | 30.55 |
| 2025-12-01 | 30.01 |
| 2025-11-28 | 30.58 |
| 2025-11-26 | 30.48 |
| 2025-11-25 | 30.31 |
| 2025-11-24 | 29.90 |
| 2025-11-21 | 30.10 |
| 2025-11-20 | 29.78 |
| 2025-11-19 | 29.69 |
| 2025-11-18 | 30.71 |
| 2025-11-17 | 30.61 |
| 2025-11-14 | 30.83 |
| 2025-11-13 | 30.64 |
| 2025-11-12 | 30.62 |
| 2025-11-11 | 30.27 |
| 2025-11-10 | 29.70 |
| 2025-11-07 | 28.88 |
| 2025-11-06 | 29.35 |
| 2025-11-05 | 29.41 |
| 2025-11-04 | 29.74 |
| 2025-11-03 | 30.45 |
| 2025-10-31 | 30.42 |
| 2025-10-30 | 30.01 |
| 2025-10-29 | 29.82 |
| 2025-10-28 | 30.19 |
| 2025-10-27 | 30.03 |
| 2025-10-24 | 30.12 |
| 2025-10-23 | 30.21 |
| 2025-10-22 | 30.48 |
| 2025-10-21 | 30.47 |
| 2025-10-20 | 29.96 |
| 2025-10-17 | 29.79 |
| 2025-10-16 | 29.21 |
| 2025-10-15 | 29.16 |
| 2025-10-14 | 29.47 |
| 2025-10-13 | 29.12 |
| 2025-10-10 | 29.15 |
| 2025-10-09 | 29.65 |
| 2025-10-08 | 30.10 |
| 2025-10-07 | 29.33 |
| 2025-10-06 | 28.80 |
| 2025-10-03 | 28.83 |
| 2025-10-02 | 29.22 |
| 2025-10-01 | 28.89 |
| 2025-09-30 | 27.99 |
| 2025-09-29 | 28.26 |
| 2025-09-26 | 27.57 |
| 2025-09-25 | 27.30 |
| 2025-09-24 | 26.92 |
| 2025-09-23 | 27.14 |
| 2025-09-22 | 27.39 |
| 2025-09-19 | 27.39 |
| 2025-09-18 | 27.67 |
| 2025-09-17 | 27.67 |
| 2025-09-16 | 27.97 |
| 2025-09-15 | 28.11 |
| 2025-09-12 | 28.20 |
| 2025-09-11 | 28.40 |
| 2025-09-10 | 27.77 |
| 2025-09-09 | 28.34 |
| 2025-09-08 | 28.25 |
| 2025-09-05 | 28.31 |
| 2025-09-04 | 28.37 |
| 2025-09-03 | 28.35 |
| 2025-09-02 | 28.66 |
| 2025-08-29 | 27.95 |
| 2025-08-28 | 28.02 |
| 2025-08-27 | 27.81 |
| 2025-08-26 | 27.68 |
| 2025-08-25 | 27.80 |
| 2025-08-22 | 28.24 |
| 2025-08-21 | 28.41 |
| 2025-08-20 | 28.19 |
| 2025-08-19 | 27.93 |
| 2025-08-18 | 27.87 |
| 2025-08-15 | 28.08 |
| 2025-08-14 | 27.90 |
| 2025-08-13 | 28.30 |
| 2025-08-12 | 27.72 |
| 2025-08-11 | 26.77 |
| 2025-08-08 | 26.20 |
| 2025-08-07 | 26.85 |
| 2025-08-06 | 27.57 |
| 2025-08-05 | 26.80 |
| 2024-08-01 | 32.82 |
| 2024-07-31 | 32.17 |
| 2024-07-30 | 32.62 |
| 2024-07-29 | 32.33 |
| 2024-07-26 | 32.14 |
| 2024-07-25 | 31.94 |
| 2024-07-24 | 31.85 |
| 2024-07-23 | 31.82 |
| 2024-07-22 | 32.18 |
| 2024-07-19 | 31.90 |
| 2024-07-18 | 31.68 |
| 2024-07-17 | 31.69 |
| 2024-07-16 | 31.73 |
| 2024-07-15 | 31.85 |
| 2024-07-12 | 31.72 |
| 2024-07-11 | 31.94 |
| 2024-07-10 | 31.90 |
| 2024-07-09 | 31.54 |
| 2024-07-08 | 31.27 |
| 2024-07-05 | 30.80 |
| 2024-07-03 | 30.52 |
| 2024-07-02 | 30.74 |
| 2024-07-01 | 30.58 |
| 2024-06-28 | 30.42 |
| 2024-06-27 | 30.66 |
| 2024-06-26 | 30.76 |
| 2024-06-25 | 30.75 |
| 2024-06-24 | 30.82 |
| 2024-06-21 | 30.42 |
| 2024-06-20 | 30.59 |
| 2024-06-18 | 30.32 |
| 2024-06-17 | 30.74 |
| 2024-06-14 | 31.20 |
| 2024-06-13 | 31.09 |
| 2024-06-12 | 30.88 |
| 2024-06-11 | 31.25 |
| 2024-06-10 | 31.36 |
| 2024-06-07 | 31.35 |
| 2024-06-06 | 31.51 |
| 2024-06-05 | 31.35 |
| 2024-06-04 | 30.82 |
| 2024-06-03 | 30.51 |
| 2024-05-31 | 29.55 |
| 2024-05-30 | 28.75 |
| 2024-05-29 | 28.63 |
| 2024-05-28 | 29.00 |
Showing the most recent 260 of 2,297 data points. The chart above shows the full history.
Related Metrics
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani